Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. The company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. The company believes their ability to identify novel drivers of disease, coupled with their proprietary library of novel and diverse chemical compounds, uniquely enables them to craft kinase therapies against new and difficult-to-drug targets.

BPMC has a unique drug discovery platform and proprietary kinase library that has enabled them to develop highly selective kinases that have the potential for less or more predictable side effects. Because the company targets subgroups of diseases with high unmet need, the regulatory pathway is also likely to be less onerous and more expedited. Similarly, Foresite Capital anticipates less pricing pressure for drugs with minimal or no competition that have a meaningful clinical benefit. Foresite Capital expects continued demand for oncology assets, and believes investor perception of strategic optionality is likely to increase as Blueprint’s assets advance, especially given the unique drug discovery platform.